Autopsy report · NCT00898937

Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast

“Funding ended”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 years 8 months after it had already started.
• Ran for about 17 years 10 months before it stopped.
• 55 participants enrolled.
• Results were posted on the registry 9 months after it ended.

Vital statistics

Status

Terminated

Sponsor

Georgetown University

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

microarray analysis; breast biopsy

Participants

55

Sites

1

Countries

United States

Trials that died the same way

• Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients
  “Funding ended prematurely” (92% match in meaning)
• Evaluation of a Novel Microfluidic Device to Purify Metastatic Lung Cancer Patients CTC (Circulating Tumoral Cells)
  “funding ending” (91% match in meaning)
• Role of FCI in the Detection of Proctosigmoiditis Caused by IBD
  “Funding period ended” (89% match in meaning)
• A Study of APR-246 in Oesophageal Cancer
  “Funding ceased” (88% match in meaning)
• Effectiveness of the Rapid Intravascular Start (RIVS) System Versus Conventional Catheter
  “Funding Stopped” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.